Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Julphar
Cipla
QuintilesIMS
McKinsey
Chubb
Daiichi Sankyo
Colorcon
AstraZeneca

Generated: December 17, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CABOMETYX

« Back to Dashboard

Clinical Trials for Cabometyx

Trial ID Title Status Sponsor Phase Summary
NCT01709435 Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors Active, not recruiting National Cancer Institute (NCI) Phase 1 This phase I trial studies the side effects and best dose of cabozantinib S-malate in treating younger patients with solid tumors that have come back or no longer respond to treatment. Cabozantinib S-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT01716715 Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Active, not recruiting National Cancer Institute (NCI) Phase 2 This randomized phase II trial studies how well giving cabozantinib-s-malate or paclitaxel works in treating patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cavity cancer. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether cabozantinib-s-malate or paclitaxel is more effective at treating patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cavity cancer.
NCT01811212 Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Suspended Exelixis Phase 2 This phase II trial studies how well cabozantinib-s-malate works in treating patients with thyroid cancer that does not respond to treatment. Cabozantinib-s-malate may stop the growth of thyroid cancer by blocking some of the enzymes needed for cell growth. Cabozantinib-s-malate may also stop the growth of thyroid cancer by blocking blood flow to the tumor.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Cabometyx

Condition Name

Condition Name for Cabometyx
Intervention Trials
Metastatic Renal Cell Carcinoma 3
Recurrent Ovarian Carcinoma 2
Recurrent Ewing Sarcoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Cabometyx
Intervention Trials
Carcinoma 17
Carcinoma, Renal Cell 9
Neoplasms 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Cabometyx

Trials by Country

Trials by Country for Cabometyx
Location Trials
United States 297
Canada 9
Australia 3
Italy 2
New Zealand 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Cabometyx
Location Trials
California 13
Pennsylvania 11
Ohio 10
Michigan 10
Illinois 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Cabometyx

Clinical Trial Phase

Clinical Trial Phase for Cabometyx
Clinical Trial Phase Trials
Phase 2 19
Phase 1/Phase 2 2
Phase 1 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Cabometyx
Clinical Trial Phase Trials
Recruiting 9
Not yet recruiting 7
Active, not recruiting 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Cabometyx

Sponsor Name

Sponsor Name for Cabometyx
Sponsor Trials
National Cancer Institute (NCI) 14
Exelixis 5
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Cabometyx
Sponsor Trials
NIH 14
Other 10
Industry 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Argus Health
Mallinckrodt
US Army
Accenture
US Department of Justice
Chubb
Fish and Richardson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.